Sentences with phrase «vaccine research professor»

Hildegund C.J. Ertl, M.D. Caspar Wistar Professor in Vaccine Research Professor, Vaccine & Immunotherapy Center

Not exact matches

Dr. Larry Corey, Principal Investigator, HIV Vaccine Trials Network; Past President and Director, Fred Hutchinson Cancer Research Center Dr. Diane Havlir, Professor of Medicine, University of California, San Francisco Moderator: Siobhan O'Connor, Time Magazine

«If they could figure out a way to streamline, it would be a lot better,» said Kim Janda, a professor of chemistry at the Scripps Research Institute in La Jolla, California, who leads a team of researchers developing a vaccine that would prevent fentanyl overdoses by keeping the drug from reaching the brain.

The long - term persistence of CD8αα + T cells where initial infection occurs may explain why patients have asymptomatic recurrences of genital herpes because these cells constantly recognize and eliminate the virus, according to Jia Zhu, Ph.D., corresponding author, research assistant professor in Laboratory Medicine at the University of Washington and an affiliate investigator in the Fred Hutch Vaccine and Infectious Disease Division.

«The best explanation for what we are seeing is that frequently, after exposure to HIV, a few cells in the genital tract are infected, without establishment of a systemic infection,» says senior investigator Eric Hunter, PhD, professor of pathology and laboratory medicine at Emory University School of Medicine, Emory Vaccine Center, and Yerkes National Primate Research Center.

Maria Elena Bottazzi leads the research, education and administration efforts of the school, is a Professor of Pediatric Tropical Medicine and the Deputy Director for the Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development.

The advantage of Novavax's approach is that a vaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine Researchvaccine can be made rapidly and in high volume, compared with the egg - based approach that's used today, says Ted Ross, an associate professor of microbiology and molecular genetics at the University of Pittsburgh's Center for Vaccine ResearchVaccine Research (CVR).

The work, published in the journal Vaccine, was led by Professor Jonathan Van Tam and Dr Louise Lansbury in the University's Health Protection and Influenza Research Group in collaboration with other scientists in the UK, Japan, Bosnia and the Netherlands.

This could lead to new HIV vaccine strategies that are able to stimulate the rare precursors of these protective antibodies,» says Professor Lynn Morris, from the National Health Laboratory Service in the Wits School of Pathology who leads the research team at the NICD.

«We are pleased to have demonstrated such a potent and durable immune response to the vaccine,» said the study's lead author, Sita Awasthi, PhD, a research associate professor of Infectious Diseases at Penn. «If found effective in clinical trials, the vaccine will have a huge impact on reducing the overall prevalence of genital herpes infections and could reduce new HIV infections as well, especially in high - burden regions of sub-Saharan Africa.»

«An RSV vaccine with this M2 - 2 deletion could tip the balance toward a better immune response, which is what we predicted based on earlier laboratory studies,» says study leader Ruth A. Karron, MD, director of the Center for Immunization Research and a professor in the Department of International Health at the Bloomberg School.

Professor Elkington highlights that more research is needed to investigate the hypothesis but if it is proved, the discovery could have major implications for the design of new vaccines and drug treatments.

«This nanoformulation approach allows us to make vaccines against new diseases in only seven days, allowing the potential to deal with sudden outbreaks or make rapid modifications and improvements,» says Daniel Anderson, an associate professor in MIT's Department of Chemical Engineering and a member of MIT's Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science (IMES).

The molecular details of our discovery will facilitate the design of new drugs and new vaccines,» said Alexis Kaushansky, PhD, an assistant professor at the Center for Infectious Disease Research.

The research was led by the paper's senior author, James Crowe Jr., M.D., the Ann Scott Carrell Professor and director of the Vanderbilt Vaccine Center.

If we can do that, then we can make flu vaccines that would be even more effective than the current vaccine,» said Professor Derek Smith from the University of Cambridge, one of the two leaders of the research, together with Professor Ron Fouchier from Erasmus Medical Center in The Netherlands.

«We thought we would need five different sets of vaccines or five different (drugs),» said James Crowe Jr., M.D., the Ann Scott Carrell Professor and director of the Vanderbilt Vaccine Center, who led Vanderbilt's end of the research.

«The discovery of this new antibiotic was an unexpected result of basic research on HIV proteins,» said senior author Ronald Montelaro, Ph.D., professor and co-director of Pitt's Center for Vaccine Researcresearch on HIV proteins,» said senior author Ronald Montelaro, Ph.D., professor and co-director of Pitt's Center for Vaccine ResearchResearch (CVR).

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

«This research emphasizes the pre-exposure of chlamydia to the gastrointestinal (GI) tract as a vaccine,» said Guangming Zhong, M.D., Ph.D., professor in the Joe R. & Teresa Lozano Long School of Medicine at UT Health San Antonio.

«Taken together, these two studies suggest that the new scalable vaccine formulation is likely to prove as effective as the original formulation — which would make it the first protective TB vaccine in humans since BCG, which was introduced almost a century ago,» said Professor Ajit Lalvani, Director of the Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London and a member of the DAR - 901 development team.

«Many physicians reported tension between the need to build trust with families by being willing to compromise on the schedule while simultaneously feeling they were putting children at risk and causing them unnecessary pain by spreading out vaccines on multiple visits,» writes Allison Kempe, MD, MPH, professor of pediatrics and director of ACCORDS (Adult and Child Center for Health Outcomes Research and Delivery Science) at the University of Colorado School of Medicine and Children's Hospital Colorado.

«We previously showed that adenovirus vector - based HIV - 1 vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical Vaccine Research at BIDMC and professor of medicine at Harvard Medical School.

Public health policy and research must overcome several barriers to developing vaccines for pregnant women, say authors Saad B. Omer, MBBS, PhD, professor of global health, epidemiology and pediatrics at Emory University and Richard H. Beigi, MD, MSc, associate professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh Medical Center and chief medical officer at Magee - Womens Hospital of UPMC.

Assistant Research Professor Institute for Immunology and Informatics Director Vaccine Research, EpiVax, Inc. 401-277-5245 [email protected]

«We've optimized a vaccine against heroin,» said Kim Janda, a professor in the chemistry and immunology department at The Scripps Research Institute (TSRI) and a senior member of the researResearch Institute (TSRI) and a senior member of the researchresearch team.

William Schief is a Professor in the Immunology and Microbial Science Department at The Scripps Research Institute in La Jolla, CA, Director for Vaccine Design at the International AIDS Vaccine Initiative (IAVI), and an Associate Member of the Ragon Institute of MGH, MIT and Harvard.

At first, analyzing a patient's surgically removed tumor and developing a vaccine against 10 specific targets on the tumor took nine months, says Greg Lizée, Ph.D., associate professor of Melanoma Medical Oncology, whose research focuses on the immune system.

He is currently an Assistant Professor and the Principal Investigator of the Viral Dynamics laboratory at the Center for Virology and Vaccine Research at the BIDMC.

Scientists have found a «blueprint» for a universal flu vaccine, according to the leader of a research project into influenza, said Professor Lalvan:

Weiner joined The Wistar Institute as the Executive Vice President, Director of the Vaccine & Immunotherapy Center, and W.W. Smith Charitable Trust Professor in Cancer Research in 2016.

Mahamadou has gained wide experience in positions such as Assistant Professor of Parasitology, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, Bamako, and Associate Professor of Parasitology - Mycology at the same university, where he currently holds two positions: Professor of Parasitology - Mycology, and he is Head of the Mali Malaria Vaccine Development Unit, Malaria Research and Training Center.

Executive Vice President Director, Vaccine & Immunotherapy Center W.W. Smith Charitable Trust Professor in Cancer Research Professor, Immunology, Microenvironment & Metastasis Program

The Wistar Institute was awarded a $ 1,494,972 grant by the Bill & Melinda Gates Foundation to advance a DNA - based vaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Revaccine candidate for protection against malarial infection utilizing a synthetic DNA platform created in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer ReVaccine & Immunotherapy Center at The Wistar Institute and the W.W. Smith Charitable Trust Professor in Cancer Research.

Executive Vice President Director, Vaccine & Immunotherapy Center W.W. Smith Charitable Trust Professor in Cancer Research

Dr. Darryn Knobel, Associate Professor of Epidemiology and Population Health at Ross University School of Veterinary Medicine, recently published his research results in the journal Vaccine.

1985 — Introduced first feline leukemia vaccine, a result of 15 years of research under the direction of Dr. Richard Olsen, professor of pathobiology.